Four things a small-molecule PV system misses
Risk accumulates across cycles, not within one
Absorbed dose builds cycle over cycle — a single-cycle safety read misses the cumulative exposure that actually determines organ risk.
The signal may not look like a classic adverse event
Marrow reserve trending down or renal clearance slowing is the safety signal — not a discrete, reportable event a standard PV workflow is built to flag.
Dosimetry is a safety input, not an imaging footnote
Where the dose goes and what reserve remains has to sit inside the safety monitoring plan — not filed separately as a nuclear medicine record.
It sits at the intersection of three disciplines
Oncology, nuclear medicine, and dosimetry each see part of the picture — the reviewer needs fluency across all three, not expertise in one.
Four recurring failure points
Dosimetry collected for imaging purposes but never wired into the safety monitoring plan as a first-class input.
A pharmacovigilance team trained on small molecules processes RLT cases competently on paper while missing the dosimetry through-line that actually governs risk.
Cumulative-dose labeling and REMS strategy started too late to shape the cycle-limiting criteria it was meant to inform.
Sites without nuclear medicine and dosimetry capability on staff, activated on enrollment timelines rather than radiation-safety readiness.
Where the judgment sits, stage by stage
Dosimetry-integrated signal definitions — marrow reserve and renal clearance thresholds, set before protocol lock.
Site readiness review confirming nuclear medicine and dosimetry capability, not just enrollment capacity.
Named physician adjudicates cumulative-dose and organ-reserve trends across cycles, not just per-cycle events.
Long-term marrow and renal function surveillance as cumulative real-world exposure builds.
Named, credentialed, and on the record
Dr. Ashok Srivastava, MD, Ph.D., MBA
President & Chief Medical Officer
Board-certified oncologist whose expertise explicitly spans radiopharmaceuticals and hematology — the two disciplines a radioligand dosimetry-safety review has to hold together. 135 oncology & hematology trials across 20 countries.
Educate · Evaluate · Execute for RLT
RLT dosimetry-safety briefing
The dosimetry-safety gap, cumulative-dose signal definitions, and site-readiness expectations — for your board and clinical team.
IHASG Readiness Assessment
A graded review of your safety governance against an RLT-specific standard, with a roadmap to Level 4.
Continuous Medical Oversight
A named physician reviewer on the Workbench, adjudicating dosimetry and organ-reserve trends as they accumulate.
Clinical briefing on RLT safety
Questions RLT programs ask us
Why isn't standard pharmacovigilance enough for radioligand therapy?
A pharmacovigilance team trained on small molecules and biologics can process RLT cases competently on paper while missing the through-line that actually governs risk: where the absorbed dose is going and what marrow or renal reserve remains.
Do you treat dosimetry as a safety input or just an imaging output?
As a first-class safety input. Cumulative absorbed dose to organs at risk is tracked alongside — not after — conventional adverse-event reporting.
Does this apply across radioligand platforms, or one specific isotope?
The dosimetry-safety discipline — marrow reserve, renal clearance, cumulative organ exposure — applies across radioligand platforms; the specific monitoring plan is scoped to your isotope and target on a call.
Talk to an RLT safety expert.
Bring us the dosimetry-integrated monitoring plan, the signal definitions, or the safety review you're building.
Book a call